Celltrion, Inc. (KRX:068270)
South Korea
· Delayed Price · Currency is KRW 176,800
-1,800 (-1.01%)
At close: Jul 16, 2025, 3:30 PM KST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2014 - 2019 |
Other | 360.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 25.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biopharmaceutical Medicines | 6,070.13B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biopharmaceutical Medicines Growth | 153.98% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Chemical Medicines | 531.39B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Chemical Medicines Growth | 3.88% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Segments | 5.82B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Segments Growth | 27.16% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Adjustments to | -3,050.04B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Adjustments to Growth | 386.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 360.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 25.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2014 - 2019 |
Other | -150.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | -100.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biopharmaceutical Medicines Operating Income | 1,199.11B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biopharmaceutical Medicines Operating Income Growth | 101.08% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Chemical Medicines Operating Income | 9.18B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Chemical Medicines Operating Income Growth | -74.35% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Segments Operating Income | 505.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Segments Operating Income Growth | 163.31% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Adjustments to Operating Income | -716.79B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Adjustments to Operating Income Growth | 503.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | -150.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | -100.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2014 - 2019 |
Domestic | 1,554.99B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Domestic Growth | -15.77% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Americas | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Americas Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia | 192.46B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia Growth | 118.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe | 1,500.81B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America | 168.09B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Central and South America | 140.96B |
Log In |
Log In |
Log In |
Log In | Upgrade
|